Oct 3, 2024
Join campaign leaders and experts at Vicente LLP and Marijuana Policy Project for an upcoming live session on Thursday, October 24 at 11 a.m. MT. We will discuss the details of various cannabis reform initiatives on the 2024 election ballot and potential opportunities in Florida, Nebraska, North Dakota, Oregon, and South Dakota's cannabis markets. Plus, panelists will provide an update on psychedelic reform in Massachusetts.
Oct 2, 2024
The 7th Annual Cannabis LAB Conference will feature Vicente Florida partner Sally Peebles, who will discuss the future of the cannabis industry as a result of federal cannabis rescheduling. Register now!
Sep 25, 2024
Register to attend this Vicente live session on Thursday, October 17 to learn about how rescheduling may impact 280E and tax planning! Vicente attorneys, along with special guest tax attorneys from HBK CPAs and Jones & Keller, will provide an update on the rescheduling process, including the timeline to a final rule and potential obstacles, along with a deep dive into 280E and tax strategies.
Sep 13, 2024
Vicente partner Jennifer Cabrera will speak on marijuana rescheduling and pathways for aspiring lawyers at the 2024 National Interdisciplinary Cannabis Symposium in New York City on September 29. Register now!
By Jason Adelstone
Sep 9, 2024
The DEA Hearing on Proposed Rulemaking for cannabis rescheduling will take place on December 2, 2024. What happens next? Read this insights article to learn about the importance of "interested persons" and the administrative law judge appointed to oversee the hearing, the anticipated timeline, the potential impact of the presidential election, and more.
By Daniel Molina, Shawn Hauser
Aug 30, 2024
With an upcoming legislative session that will consider medical cannabis expansion, hemp regulation, decriminalization, and other cannabis matters—we have our eyes on Texas! Read the first blog of our Texas series which covers updates on cannabis reform and decriminalization measures in cities like Dallas and Austin, which are set to be on the ballot in November.
Aug 28, 2024
Vicente LLP Michigan-based partner Travis Copenhaver will discuss opportunities and challenges for the cannabis industry in response to federal marijuana rescheduling at NECANN Michigan on September 20. Register for the conference and contact us to schedule a meeting with Travis!
By Shawn Hauser
Aug 1, 2024
Last Monday marked the end of the historic DEA public comment period for marijuana’s proposed rescheduling to Schedule III. What happens now and how might election dynamics have an impact?
By Jason Adelstone
Jul 24, 2024
Despite growing public support, EU nations face significant legal hurdles in establishing commercial marijuana markets due to international drug treaties and EU regulations. This Insights post highlights the various approaches toward cannabis reform taken by countries like Germany, Malta, the Netherlands, Switzerland, and the Czech Republic, and how this could potentially impact future cannabis policies in Europe.
By Shawn Hauser
May 29, 2024
We are at a historic and critical moment for cannabis reform, as the DOJ and HHS/FDA have proposed rescheduling cannabis to Schedule III. The DEA is accepting public comments until July 22, 2024 via the Federal eRulemaking Portal, so now is the time to take action and make your voice heard!
By Jason Adelstone
May 21, 2024
The DEA published its proposed rule to move marijuana from schedule I to schedule III on May 21, and the 60-day public comment period has officially opened. The DEA also published an opinion from the Office of Legal counsel that provides a thorough analysis supporting why placing marijuana in schedule III is appropriate and legally justified. Read this insight for a high-level overview of the proposed rule and the OLC Opinion.
By Jason Adelstone
May 20, 2024
In a recent House Committee meeting with DEA Administrator Anne Milgram, Rep. Andrew S. Clyde voiced his opposition to removing marijuana from Schedule I based on public safety reasons, but then contradicted himself by stating marijuana is “not as dangerous as some of the others we have talked about” (the meeting focused primarily on fentanyl’s harms to communities). This blog post addresses the false narratives and misconceptions that opponents of cannabis reform continue to promote.
May 7, 2024
On May 8, Vicente’s director of economics and research, Andrew Livingston, is joining Rootwurks for a webinar to break down what it will mean for the cannabis industry now that the DEA is making moves to reclassify cannabis into schedule III—and what work for legalization remains to be done. Register now!
By Shawn Hauser
May 7, 2024
Vicente LLP partner Shawn Hauser argues in a new Marijuana Moment op-ed that the federal decision to reschedule cannabis is “a historic and critically important shift”—with the government “finally (and officially) recognizing the efficacy and safety of cannabis for medical use.”
May 3, 2024
Watch this special briefing featuring Vicente LLP leaders who have been deeply immersed in the federal scheduling issue, along with Mitzi Keating, a CPA and partner at Citrin Cooperman.
By Jason Adelstone
Apr 29, 2024
After listening to the House Oversight and Accountability Committee Hearing with the Commissioner of the FDA on April 11, one conclusion was reinforced—opponents of marijuana reform are misinformed and rely on misstating facts to support their position. Those against moving marijuana into schedule III are making their voices heard, but almost universally, those voices simply do not understand what schedule III would mean.
By Jason Adelstone
Jan 30, 2024
On August 29, 2023, the Department of Health and Human Services (“HHS”) sent the Drug Enforcement Administration (“DEA”) its recommendation to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (“CSA”). Since then, the marijuana industry has waited in suspense for the DEA to make the final call as to what schedule marijuana will be placed. Read this Insights post that outlines the complex process of marijuana rescheduling in the US and outlines the key steps involved, from rule publication to review and final rule, emphasizing the critical role of stakeholder engagement in securing a Schedule III classification.
By David M. Ullian, Gabriel Amatruda
Oct 5, 2023
Public support for medical cannabis in North Carolina is quite strong and despite being one of only a few states that have legalized medical or adult use, cannabis is finally making headway in the Tar Heel State. Read this article to learn about recent cannabis and hemp developments in NC, including legislation and the Eastern Band of Cherokee Indians’ vote to legalize adult-use cannabis.
Oct 4, 2023
Watch this special briefing where Vicente LLP leaders share insights on the impacts of the HHS recommendation to reschedule cannabis and outline the road ahead.
By Shane Pennington
Nov 9, 2022
What outcomes are possible from the impending administrative process to reconsider cannabis’s schedule I status? What are the implications of those various possible outcomes? And how should we all proceed in light of it all?
By Shane Pennington
Oct 21, 2022
To appreciate the gravity of the President’s scheduling directive and what could happen next, you need to understand (1) how the administrative process the President has set in motion will actually work and (2) how the agencies in charge have used it to affirm and reaffirm cannabis’s schedule I1 status repeatedly throughout the Comprehensive Drug Abuse Prevention and Control Act of 1970’s (“CSA”) history. Those topics are covered in this article.
By Jennifer Flanagan
Aug 26, 2022
Jennifer Flanagan writes for the Worcester Telegram & Gazette, reflecting on the Commonwealth's first major cannabis reform legislation since Massachusetts established a regulated adult-use cannabis market.